Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

Abroad (travel likely)Recruiting

Conditions

Hepatocellular Carcinoma Non-resectable

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Contact: Study coordinator (Zhi-Bo Zhang) · zbzhang_1234@163.com · 13960986516
Fujian Provincial Hospital, Fuzhou, Fujian, China
Contact: Study coordinator (Shao-Ming Wei) · 67468424@qq.com · (+86)13599037493
Fujian provincial hospital, Fuzhou, Fujian, China
Contact: Study coordinator (Mao-Lin Yan) · yanmaolin74@163.com · 0591-88217140
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
Contact: Study coordinator (Yong-Yi Zeng) · lamp197311@126.com · 13805083802

Study leads

Shao-Ming Wei
Principal Investigator
Fujian Provincial Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Changsha, China

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Carcinoma, Hepatocellular · Hepatocellular Cancer · Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · Los Angeles, United States

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

Hepatocellular Carcinoma

Abroad (travel likely)Recruiting

Ancona, Italy · Bergamo, Italy